Novartis - Q1 FY2026 Earnings Analysis

Performance Highlights

Novartis reported Q1 2026 net sales of USD 13.1 billion, down 1% in USD and 5% in constant currency versus the prior-year quarter, missing consensus expectations as 14 percentage points of generic headwinds overwhelmed 13 percentage points of volume growth. Core EPS declined 13% in USD to USD 1.99, while core operating income margin contracted 4.8 percentage points to 37.3%, reflecting both the revenue shortfall and a 16% step-up in R&D investment to USD 2.7 billion.

The single most important operating driver was the accelerating performance of priority growth brands, which collectively offset but could not fully neutralize the loss of Entresto exclusivity in the US, where segment sales fell 42% to USD 1.3 billion. Kisqali surged 55% cc to USD 1.5 billion on early breast cancer momentum, Pluvicto rose 70% cc to USD 642 million on pre-taxane prostate cancer demand, Scemblix grew 79% cc to USD 433 million, Leqvio gained 69% cc to USD 452 million, and Fabhalta more than doubled to USD 169 million, collectively demonstrating deep commercial breadth across oncology, immunology, and cardiovascular-renal-metabolic franchises.

Management Outlook and Forward Catalysts

Management reaffirmed full-year 2026 guidance for low single-digit net sales growth and low single-digit core operating income decline in constant currencies, signalling confidence that H2 generic headwinds will moderate as the Entresto base effect normalises. CEO Vas Narasimhan highlighted multiple anticipated H2 data readouts — including the del-desiran Phase III HARBOR trial in myotonic dystrophy, pelacarsen in Lp(a) cardiovascular prevention, and a Phase III food allergy program launch for remibrutinib — as potential catalysts capable of raising the mid- to long-term growth outlook.

The central investor debate for Q2 and beyond centres on whether the Avidity acquisition, which added USD 12.0 billion of net cash outflow and drove net debt to USD 38.1 billion from USD 21.9 billion at year-end, can generate pipeline returns that justify the leverage expansion, while bears will scrutinise the pace of Entresto generic erosion stabilisation, Pluvicto's EMA withdrawal risk overhang, and the ianalumab Phase III miss in warm autoimmune hemolytic anemia as signals of pipeline execution risk.